Dyadic International, Inc. (NASDAQ:DYAI) Q4 2023 Earnings Call Transcript

Operator: [Operator Instructions] There are no further questions in the queue, I’d like to hand it back to Mark Emalfarb for closing remarks.

Mark Emalfarb: In fiscal year 2023, we are witnessing the positive impact of our Phase I human clinical safety trial, further validating the C1 platform potential for pharmaceutical use in both human and animal health. Moreover, the investment in our Dapibus platform for alternative proteins and enzymes is beginning to yield revenue, marking a significant milestone. Our primary focus remains on enhancing Dyadic value within the life science industry, which in turn benefits our shareholders and promote global access to affordable vaccines and therapeutics. We refined our focus and adjusted our business strategies to capitalize on existing and emerging commercialization opportunities in the near-term, aligning with our mission as a global biotechnology company to revolutionize how we feed fuel and heal the world.

The company remains dedicated to driving near-term revenue and growth through innovation and commercialization efforts, expanding the use of Dapibus platform for developing alternative for common proteins such as alpha-lactalbumin or common human albumin and non-animal dairy enzymes for food production across various other applications. Once again, I cannot overstate how exciting this time is in Dyadic’s history. We are uniquely positioned to rapidly capitalize on the present opportunities and those on the horizon. Thank you for joining us in today’s fiscal year 2023 conference call. We look forward to keeping you informed as we progress in commercial and scientific endeavors during our next call. Please stay tuned for additional updates from us.

Operator: Ladies and gentlemen, this does conclude today’s teleconference. Thank you for your participation. You may disconnect your lines at this time, and have a wonderful day.